Archive | Clinical Trials

T-cell redirection therapy shows durable response for metastatic uveal melanoma

Immunocore Limited presented data from the IMCgp100-102 trial at the American Society of Clinical Oncology meeting that showed a durable response and strong overall survival rate in patients with metastatic uveal melanoma.

Read the full story

Posted in Melanoma In The News, Clinical Trials

T-VEC Immunotherapy Shows Promising Early Activity in Melanoma

Twelve weeks of neoadjuvant exposure to talimogene laherparepvec (T-VEC) was associated with few high-grade toxicities and a promising pathological complete tumor-response (pCR) rate

Read the full story

Posted in Melanoma In The News, Clinical Trials

Encorafenib plus binimetinib prolongs OS for advanced BRAF-mutated melanoma

Combination therapy with encorafenib plus binimetinib significantly improved OS compared with vemurafenib or encorafenib alone for patients with advanced BRAF-mutated melanoma, according to phase 3 results from the COLUMBUS trial presented at ASCO Annual Meeting.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Combination therapy with SD-101, pembrolizumab shows promise for metastatic melanoma

Intralesional agent SD-101 plus pembrolizumab induced a high response rate with a tolerable safety profile among a small cohort of patients with metastatic melanoma, according to results of a phase 1b/phase 2 trial presented at ASCO Annual Meeting.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories